Thomson Medical Group Ltd. (SG:A50)
SGX:A50
Top Page
Thomson Medical Group Ltd.
(SGX:A50)
Select Model
Select Model
Rating:46Neutral
Price Target:
S$0.06
▼(-8.33% Downside)
Action:ReiteratedDate:01/08/26
Overall score is held back primarily by weak financial performance (declining revenue, negative profitability, high leverage, and poor free cash flow trends). Technicals are a bright spot with price trading above major moving averages and positive MACD, but valuation is undermined by losses (negative P/E) and no dividend yield support.
Positive Factors
High gross margin
A 74.8% gross margin indicates strong unit economics for core services, supporting coverage of fixed hospital costs. Over the medium term this margin buffer helps absorb revenue volatility, fund operational improvements and sustain service-level profitability if overheads are reined in.
Negative Factors
High financial leverage
A debt-to-equity near 2.4 signals elevated leverage that raises interest and refinancing pressure. For a capital-intensive hospital operator this constrains flexibility for facility upgrades, strategic investments or weathering prolonged volume downturns without raising costly funding.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin
A 74.8% gross margin indicates strong unit economics for core services, supporting coverage of fixed hospital costs. Over the medium term this margin buffer helps absorb revenue volatility, fund operational improvements and sustain service-level profitability if overheads are reined in.
Read all positive factors
Thomson Medical Group Ltd. (A50) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$1.48B
Dividend YieldN/A
Average Volume (3M)2.14M
Price to Earnings (P/E)―
Beta (1Y)0.63
Revenue Growth12.39%
EPS Growth-400.00%
CountrySG
Employees2,185
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.00
Shares Outstanding26,443,615,000
10 Day Avg. Volume2,062,170
30 Day Avg. Volume2,143,033
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.41
Price to Sales (P/S)2.88
P/FCF Ratio33.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
S$0.06Price Target Upside0.00%
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)S$425.40M
Thomson Medical Group Ltd. Business Overview & Revenue Model
Company Description
Thomson Medical Group Limited, an investment holding company, provides healthcare services for women and children in Singapore, Malaysia, and Vietnam. The company owns and operates the Thomson Medical Centre, as well as a network of medical clinic...
How the Company Makes Money
Thomson Medical Group makes money primarily by charging for healthcare services delivered through its private hospital operations. Key revenue streams typically include (1) inpatient and outpatient clinical fees from consultations, diagnostics, pr...
Thomson Medical Group Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
40
Negative
Cash Flow
35
Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 394.66M | 351.15M | 355.77M | 333.71M | 240.40M |
| Gross Profit | 295.33M | 275.39M | 296.39M | 278.38M | 116.02M |
| EBITDA | 57.72M | 109.08M | 106.78M | 110.72M | 59.54M |
| Net Income | -47.58M | 14.16M | 36.55M | 53.76M | 14.24M |
Balance Sheet | |||||
| Total Assets | 1.78B | 1.81B | 1.45B | 1.36B | 1.29B |
| Cash, Cash Equivalents and Short-Term Investments | 124.21M | 167.28M | 286.59M | 161.59M | 114.51M |
| Total Debt | 1.12B | 1.12B | 762.79M | 642.86M | 631.08M |
| Total Liabilities | 1.24B | 1.23B | 872.34M | 756.60M | 719.74M |
| Stockholders Equity | 470.89M | 499.72M | 499.44M | 531.68M | 489.84M |
Cash Flow | |||||
| Free Cash Flow | 33.79M | 52.99M | 75.81M | 64.68M | 23.96M |
| Operating Cash Flow | 60.45M | 83.35M | 88.59M | 92.80M | 61.25M |
| Investing Cash Flow | -27.16M | -489.99M | -13.39M | -29.44M | -37.57M |
| Financing Cash Flow | -71.19M | 281.32M | 54.22M | -23.48M | -58.82M |
Thomson Medical Group Ltd. Technical Analysis
Positive
0.06
Price Trends
0.06
Positive
0.06
Negative
0.06
Positive
Market Momentum
>-0.01
Negative
54.94
Neutral
83.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:A50, the sentiment is Positive. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.06, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.94 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:A50.
Thomson Medical Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
SG:A50
Thomson Medical Group Ltd.
0.06
0.02
38.10%
RAFLF
Raffles Medical Group
0.80
0.07
9.32%
SG:40T
ISEC Healthcare Ltd
0.34
>-0.01
-2.33%
SG:5WA
OUE Lippo Healthcare Limited
0.03
<0.01
40.00%
Thomson Medical Group Ltd. Corporate Events
TMC Life Sciences Issues Unaudited Interim Results for December 2025 Quarter
Feb 9, 2026
TMC Life Sciences Berhad has released its unaudited interim financial report for the financial quarter ended 31 December 2025, providing stakeholders with an early view of its financial performance. The disclosure signals the company’s ongoi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.